DIRS.INFO The most relevant business & tech news

☆ Marcelo Claure and Paul Judge bought SoftBank's diversity fund. Now they're trying to raise $200 million for it.
▼ + stars: | 2024-02-01 | by ( Vishal Persaud | ) www.businessinsider.com time to read: +6 min

Read previewFormer SoftBank executive Marcelo Claure and serial entrepreneur and investor Paul Judge are in the throes of raising a new $200 million fund. The past year has been transitional for the fund since Claure and Judge bought the $100 million fund from SoftBank. Since then, there haven't been any new investments, but the two are poised to capitalize on the success of the first fund and are raising the second Open Opportunity Fund. He said that limited partners' interest has been positive overall since the Open Opportunity Fund's first fund has had so much success. AdvertisementJudge said that he expects the first Open Opportunity Fund to continue to deliver "top quartile" returns to its investors over the next five to seven years.

Persons: —, Marcelo Claure, Paul Judge, It's, Claure, haven't, SoftBank —, I've, Judge, George Floyd's, Masayoshi, Shu Nyatta, Stacy Brown, what's Organizations: Service, Business, Opportunity Fund, Opportunity, Fund, Mastercard, Vista Equity Partners, Ventures, Sprint, Bicycle Capital, TechCrunch Locations: SoftBank, Atlanta, America

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., August 15, 2023. Traders in the U.S. equity options market are bracing for a larger-than-usual swing in Nvidia shares following the chipmaker's earnings, which are due after markets close on Wednesday. ET, Dow e-minis were up 34 points, or 0.1%, S&P 500 e-minis were up 4.25 points, or 0.1%, and Nasdaq 100 e-minis were up 4.75 points, or 0.03%. Peloton Interactive (PTON.O) shares plunged 27% after the fitness equipment maker forecast first-quarter revenue below estimates. Reporting by Amruta Khandekar and Shristi Achar A; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Foot, Susannah Streeter, Hargreaves Lansdown, Jerome Powell, Roche, Armour, Amruta Khandekar, Shinjini Organizations: New York Stock Exchange, REUTERS, Nvidia, Sports, Dow, Nasdaq, Wall, Hargreaves, Traders, Reuters, Federal Reserve, Treasury, Dow e, Biosciences, Merck & Co, Sport, Nike, Thomson Locations: New York City, U.S, Swiss

BERLIN, Aug 23 (Reuters) - Roche (ROG.S) inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy. Roche said on Wednesday that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab, part of an experimental class of drugs known as anti-TIGIT. The data lifted Roche shares by 5% and sent shares of other companies testing anti-TIGIT drugs higher. J.P. Morgan analysts said the interim data suggested a survival benefit was within reach in the final analysis, but the clinical relevance remained uncertain. The unintended disclosure regards the second interim analysis of a Phase III trial known as Skyscraper 1.

Persons: Roche, tiragolumab, Morgan, Roche's, TIGIT, Paul Arnold, Christy Santhosh, Jason Neely, Friederike Heine, Mark Potter Organizations: Merck & Co, Gilead Sciences, iTeos Therapeutics, Arcus Biosciences, Thomson Locations: U.S, Zurich, Bengaluru

LONDON, July 28 (Reuters) - French telecoms firm TDF is studying options for its fibre business including a sale, four people familiar with the matter told Reuters, in a deal that could value the fibre unit upwards of 1 billion euros. The sellers are looking for as much as 1.3 billion to 1.6 billion euros for the fibre unit, according to one of the people, a price that buyers may find difficult to swallow. TDF - a former unit of France's leading telecoms operator Orange - provides broadcasting, fibre and telecoms infrastructure with some of its radio antennas sitting on top of the Eiffel Tower in Paris. The fibre unit's EbitdaAL, which deducts the cost of the leases from EBITDA, reached 28.7 million euros last year up from 21.6 million euros a year earlier, while revenues grew 42.8% to 52 million euros, according to TDF’s latest annual results. Two of the sources said the fibre unit's valuation will depend on the number of homes connected to fibre, market penetration and growth rate.

Persons: Brookfield, Sweden's, Les Echos, Andres Gonzalez, Amy, Jo Crowley, Jonathan Oatis Organizations: TDF, Reuters, Brookfield Asset Management, BNP Paribas, BNP, Brookfield, Orange, Eiffel, Sweden's EQT Partners, PSP Investments, APG, Management, Arcus Infrastructure Partners, Agricole, CAA, Thomson Locations: Paris, Europe, TDF, EBITDA

☆ Cancer drugmakers rise as industry meet fuels investor interest
▼ + stars: | 2023-06-05 | by ( ) www.reuters.com time to read: +2 min

June 5 (Reuters) - Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago. ImmunoGen Inc's experimental drug, Elahere, to treat a type of ovarian cancer showed 35% reduction in the risk of tumor progression or death compared to chemotherapy in a late-stage study. Shares of Evaxion rose 5.4% to $1.55 after the smaller drug developer said its vaccine to prevent a type of skin cancer met safety goals in an early-stage study. Shares of Blueprint Medicines Corp (BPMC.O) fell 9.4% to $52.76 after analysts flagged potential safety issues about its experimental drug to treat a type of lung cancer. Reporting by Manas Mishra and Mariam Sunny in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Persons: William Blair, Manas Mishra, Mariam Sunny, Shailesh Organizations: Immunogen Inc, Evaxion, Therapeutics, American Society of Clinical Oncology, Arcus, Medicines Corp, Thomson Locations: Chicago, Bengaluru

Wall Street's main indexes continued their losing streak for a fourth straight session on Monday as investors shied away from riskier bets, worried that the Federal Reserve's interest rate hikes could push the U.S. economy into recession. The Fed has managed to slow the economy down so it's likely that earnings estimates (for Q4) are going to come down. Treasuries fell following the BOJ's shock move, with the benchmark 10-year Treasury yield rising to a three-week high of 3.66%. Earlier, data showed U.S. single-family homebuilding tumbled in November as higher mortgage rates continued to depress housing market activity. A slew of other economic data due this week including consumer confidence and core inflation will provide more clues to investors on future interest rate hikes.

☆ A top Wall Street analyst names 6 major events that could send biotech stocks soaring between now and the end of 2022
▼ + stars: | 2022-11-14 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +5 min

Cantor Fitzgerald analysts named six big events to mark on your calendar. While the majority of the expected events are set to come from smaller biotech companies, bigger companies — like Roche, Gilead, and Alnylam — have their own events coming through the pipeline. Here are the six major events from big biotech companies that could send stocks soaring:1. Cantor Fitzgerald analysts give Gilead's stock a neutral rating and they have an overweight rating on Arcus. Lenacapavir "could become a much bigger piece of the HIV growth narrative over the next few years," according to Cantor Fitzgerald analysts.

☆ These companies are cheap, have strong balance sheets, and analysts love them
▼ + stars: | 2022-10-26 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

The S & P 500 is down about 19% in 2022, while the Nasdaq has dropped about 29% in that time. Advanced Micro Devices has a price-to-book value of 1.7, with a total debt as a percentage of equity of 5.8%, according to FactSet data. Salesforce has a price-to-book value of 2.7, with a total debt as a percentage of equity of just 23.8%. Knight-Swift Transportation has a price-to-book value of 1.2. It has a total debt as a percentage of equity of 25.8.

Organizations: & $

☆ Undă verde pentru concertele sub cerul liber. Mai mulți muzicieni au interpretat piese cunoscute de jazz pe scena Teatrului Verde
▼ + stars: | 2021-05-13 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

Agenda culturală a pornit seara trecută, cu muzică jazz la Teatrul Verde din Capitală. "E o gașcă super minunată se adună toţi muzicienii din breasla de jazz. "Am mai fost tot la jazz, dar a fost un an în urmă când a început pandemia.Vrem să ascultăm muzică şi să ne odihnim. Şi noi am încercat să îi susţinem şi să venim să ascultăm muzică jazz. Muzicienii vin să comunicie fiecare în limbajul lui.

Persons: Alex Arcuș Locations: Capitală, Moldova, România, București, Chişinău

Search resuls for: "Arcus"

9 mentions found